« Back
Home /
Ningetinib

Ningetinib

Item no.	HY-107145A-10mM
Manufacturer	MedChem Express
CASRN	1394820-69-9
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Colorectal Cancer Brain Cancer
Type	Inhibitors
Specific against	other
Purity	99.82
Citations	[1]Ning Xi, et al. Abstract 1755: CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth. Cancer Res 2014;74(19 Suppl):Abstract nr 1755.
Smiles	CC1=C(C(NC2=CC(F)=C(OC3=CC=NC4=C3C=CC(OCC(C)(O)C)=C4)C=C2)=O)C(N(C5=CC=CC=C5)N1C)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1394820-69-9
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	c-Met/HGFR; TAM Receptor; VEGFR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	556.58
Product Description	Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and c-Met, VEGFR2 and Axl, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 12.5 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Isoform	Axl; VEGFR2/KDR/Flk-1
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-107145A-10mM-safety-datasheet.pdf